Legislation · Canada (Federal) · Federal
S-201 — An Act respecting a national framework on sickle cell disease
Clarion tracks S-201 before Canada (Federal) — its status, sponsor, plain-language summary, and every stage it moves through, each cited to the official record.
- Status
- In committee — House of Commons
- Sponsor
- Marie-Françoise Mégie
- Introduced
- 2025-05-28
- Session
- 45-1
See what's moving in Canadian policy — get The Dispatch, our free weekly read.
What it does
AI plain-language summary of the official text.
Senate Public Bill S-201, the National Framework on Sickle Cell Disease Act, seeks to establish a national framework for addressing sickle cell disease in Canada. Introduced in the Senate, the bill passed through Senate stages including committee consideration and third reading before being transmitted to the House of Commons. It is currently under review by a House committee at the second reading stage. The bill reflects a legislative effort to coordinate a pan-Canadian response to sickle cell disease.
Passage outlook
Contested because it's a Senate public bill (which rarely passes), it's at committee.
Historically 10–30% of comparable federal bills became law (base rate 19%).
A transparent, rule-based outlook from bill type, stage, and verified government standing — not a guaranteed prediction.
Stage timeline
Second reading
2026-06-16House
First reading
2025-12-11House
Third reading
2025-11-18Senate
Consideration in committee
2025-10-23Senate
Second reading
2025-06-12Senate
First reading
2025-05-28Senate
Track S-201 — and everything like it
Set a topic, and Clarion grades the bills, debates, and lobbying filings it ingests to your files — with a calibrated passage forecast and an AI clerk that answers from the record and cites it.